Aquestive Q2 net loss $13.5M; FDA accepts Anaphylm NDA, PDUFA Jan 31, 2026

Aquestive Therapeutics, Inc.

2025-Q2 EPS reported -$0.37 vs consensus -$0.17 ▼ miss (-115.5%)

Total revenue $10.0M, down 50% YoY; excluding one-time deferred revenue, up 3% to $10.0M.
Net loss $13.5M ($0.14/sh) vs $2.7M loss ($0.03) in Q2 2024; adjusted EBITDA loss $9.3M.
Cash $60.5M at June 30; FY2025 guidance: revenue $44-50M, adjusted EBITDA loss $47-51M.
FDA accepted Anaphylm NDA; PDUFA date Jan 31, 2026; Q1 2026 launch planned if approved.
Anaphylm global expansion to Canada and EU; AQST-108 IND for alopecia areata expected Q4 2025.

item 2.02item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.